News
Better Buy: Eli Lilly vs. Viking Therapeutics
Comparing Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) might initially seem odd. The two drugmakers don't seem to have much in common. Eli Lilly is more than 50 times the size of
Which Hyper-Yield Stock Should Retirees Trust With Their Money? Altria Group's 9.5% Yield or AT&T's 6.6%?
Retirees and other income-focused investors must wade through an ocean of dividend stocks to find high-yield investments that can afford their lofty payout. The market won't pay as much for a stock
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
After rising by 137% in one day upon the publication of favorable phase 2 clinical trial results on Feb. 27, Viking Therapeutics (NASDAQ: VKTX) is now doubtlessly on many investors' radars. Soon
1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Given its key role in the fight against COVID-19, the fact that Pfizer (NYSE: PFE) shares are down 56% from their 2021 peak isn't entirely surprising. Demand for its COVID-19 vaccine (Comirnaty) and
Plug Power Stock Has 16% Upside, According to 1 Wall Street Analyst
From the start of the year through the end of trading last week, Plug Power (NASDAQ: PLUG) stock has vastly underperformed the market. Whereas the S&P 500 rose 7.4% during this time frame, share
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
Technically, there is no upper limit to how much money investors can make from stocks in five years, but turning $1,000 into $2,500 is no easy task. That requires a compound annual growth rate
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Since 2021, shares of Novavax (NASDAQ: NVAX) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Why Plug Power Stock Surged 13.7% Thursday Morning
Plug Power (NASDAQ: PLUG) stock kicked off Thursday on a high note, surging 13.7% in early-morning trading. An analyst upgrade just ahead of earnings is fueling investor interest in the hydrogen
Is AbbVie Stock a Buy Now?
Pharmaceutical giant AbbVie (NYSE: ABBV) is undergoing significant changes. Last year, the company lost U.S. patent exclusivity for its biggest cash cow, immunosuppressant Humira, and is now seeing
Viking Therapeutics: A Teachable Moment About Investing for the Long Term
On Tuesday, Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech specializing in treatments for metabolic diseases, saw its stock price surge by a staggering 121% in response to a clinical
Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?
The weight loss drug market is growing in leaps and bounds -- and today the biggest winners are Eli Lilly and Novo Nordisk. These big pharma companies are bringing in billions thanks to their drugs
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
Just one day after the ascendant biotech CRISPR Therapeutics (NASDAQ: CRSP) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
You've no doubt seen mutual fund warnings that past performance isn't necessarily indicative of future results. This caution applies to stocks as well. However, it doesn't just mean that investments
Is Viking Therapeutics a Buy Now?
Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, more than doubled recently. The market started hurling money at the stock after some mid-stage clinical trial results
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q4 2023 Earnings CallFeb 28, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Geron (GERN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q4 2023 Earnings CallFeb 28, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Is It Too Late to Buy Sarepta Therapeutics Stock?
Sarepta Therapeutics (NASDAQ: SRPT), a midcap biotech company, was riding high 18 months ago. The company was awaiting a crucial regulatory approval from the U.S. Food and Drug Administration (FDA)
EQS-News: Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
MannKind (MNKD) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q4 2023 Earnings CallFeb 27, 2024, 5:00 p.m. ET
Operator
Source Fool.com
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
The arrival of a potential new rival in an important product category dinged the share prices of pharmaceutical companies Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) on Tuesday. Both slumped
Pfizer Stock Has 30% Upside, According to 1 Wall Street Analyst
With Pfizer (NYSE: PFE) stock hovering near a five-year low, one analyst has just started coverage of the pharmaceutical giant and is telling investors it's time to buy. In a report released last